BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
Ashley M PriceSamantha M OlsonMargaret M NewhamsNatasha B HalasaJulie A BoomLeila C SahniPia S PannarajKatherine IrbyKatherine E BlineAline B MadduxRyan A NofzigerMelissa A CameronTracie C WalkerStephanie P SchwartzElizabeth H MackLaura SmallcombJennifer E SchusterCharlotte V HobbsSatoshi KamidaniKeiko M TarquinioTamara T BradfordEmily R LevyKathleen ChiotosSamina S BhumbraNatalie Z CvijanovichSabrina M HeidemannMelissa L CullimoreShira J GertzBria M CoatesMary A StaatMatthew S ZinterMichele KongBrandon M ChataniJanet R HumeKatri V TyppoMia MaamariHeidi R FloriMark W TenfordeLaura D ZambranoAngela P CampbellManish M PatelAdrienne G Randolphnull nullPublished in: The New England journal of medicine (2022)
BNT162b2 vaccination reduced the risk of omicron-associated hospitalization by two thirds among children 5 to 11 years of age. Although two doses provided lower protection against omicron-associated hospitalization than against delta-associated hospitalization among adolescents 12 to 18 years of age, vaccination prevented critical illness caused by either variant. (Funded by the Centers for Disease Control and Prevention.).
Keyphrases